|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
      |
|||||||||||||
 |
 |
|||||||||||||
   
 |
||||||||||||||
News
MiMedx Signs Exclusive License for NDGA Technology
Tampa, Fla. — January 29, 2007 — MiMedx Inc. (MDX), an R&D company specializing in connective tissue technology, announced today that it has signed an exclusive license with Shriner’s Hospital for Children (SHC) and the University of South Florida Research Foundation (USF) for Dr. Thomas Koob’s NDGA technology.
The strength of the core technology licensed to MiMedx is embodied in Dr. Koob’s patent. It covers the polymerization chemistry of NDGA as applied to any biological material, bioprosthesis or device created through its application. NDGA is a potent natural antioxidant of plant origin and can be found in the creosote bush.
MiMedX will initially focus on commercializing biomaterial-based products indicated for connective and soft tissue repair. The Company’s first target will be products for the repair of injuries to musculoskeletal system.
“MiMedx is transforming the way we treat connective tissue injuries,” remarked MiMedx Chairman, Steve Gorlin. “Through ongoing collaboration, we plan to further refine this innovative technology, opening up countless new possibilities.”
About Shriner’s Hospital for Children
Shriners Hospitals for Children is a network of 22 pediatric hospitals in the U.S., Canada and Mexico that provide specialized care for orthopaedic conditions, burns, spinal cord injuries and cleft lip and palate. Eligibility for care is not based on financial need or relationship to a Shriner.
About the University of South Florida Research Foundation
The University of South Florida Research Foundation was established in June 1989 to promote, encourage and provide assistance to the research activities of University faculty , staff and students. This not-for-profit organization provides a means by which discoveries, inventions, processes and work products of the USF faculty, staff and student can be transferred from the University laboratory to benefit the public. Funds generated by such discoveries are used to enhance research at the University.
About MiMedx, Inc.
Founded in 2006, MiMedx Inc. (MDX) is a development stage company whose technology focuses on biomaterials for soft tissue repair, such as tendons, ligaments and cartilage, as well as other biomaterial-based products for numerous other medical applications. The company, headquartered in Tampa, Florida, holds an exclusive, worldwide license from the Shriner’s Hospital for Children and the University of South Florida Research Foundation for its NDGA technology. MDX is targeting this proprietary technology for a myriad of diverse applications. Additional information is available at www.mimedx.com.
###
These statements have not been reviewed by the FDA.
This website is not meant as a substitute for professional medical advice.
|
|
 |
|
